< Back to Press

ASCENSIA DIABETES CARE ANNOUNCES GLOBAL INTEGRATION OF THE EVERSENSE CGM SYSTEM WITH APPLE HEALTH

Parsippany, United States

Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR^® Blood Glucose Monitoring (BGM) System portfolio and distributor of the Eversense^® Continuous Glucose Monitoring (CGM) System, announces that the Eversense^® CGM app has been updated globally to seamlessly integrate with Apple Health^TM. This means that people with diabetes using Eversense CGM Systems will now also have the option to view their glucose data within the Apple Health app, alongside other health metrics on the iPhone’s widely used health and wellbeing platform.

Developed by Senseonics Holdings, Inc. (NYSE American: SENS), the exceptionally accurate and fully-implantable Eversense E3 is the longest-lasting CGM available, with up to a 6-month sensor wear duration. The system transmits data to the Eversense CGM App where users can easily view, analyse and share glucose data, and are alerted to changes and trends. With this update, users in all markets where Eversense is available can now choose to display their data in Apple Health, where they will also be able to view health data collected by their iPhone through various apps and wearables. This integration aims to improve diabetes management by allowing Eversense users to easily view their glucose data within their wider digital health environment.

“We are pleased to integrate the Eversense CGM system with Apple Health^TM, giving our users more choice on how they view and use data for their diabetes management,” said Elaine Anderson, Head of the Eversense CGM Business Unit at Ascensia Diabetes Care. “Supplementing the benefits of the Eversense CGM App, this update allows people with diabetes to access glucose data alongside other important metrics to provide a more holistic view of their health and wellbeing. In an increasingly digital world, it is important that medical devices and digital solutions are interoperable, and we are excited to further embed Eversense into the connected healthcare ecosystem.”

Ascensia Diabetes Care is committed to putting the power of information, data and advanced analytics in the hands of patients and is working alongside Senseonics to make Eversense interoperable with more diabetes devices and digital platforms. Together, the companies are executing plans to achieve iCGM (integrated CGM) approval and integration with automated insulin delivery (AID) systems, as well as actively seeking industry collaborations that will maximize the benefits of Eversense for the diabetes community.

Eversense CGM Systems and the Eversense CGM App are available across the US and Europe. Please visit www.ascensia.com/eversense for more information.

Notes for Editors

About Senseonics

Senseonics Holdings, Inc.  is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM Systems, Eversense^® E3, includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.

We are home to the world-renowned CONTOUR^® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense^® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 125 countries. Ascensia has around 1,500 employees and operations in 31 countries. For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com

About PHC Holdings Corporation

PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia, and LSI Medience Corporation. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2021 were JPY 340 billion with global distribution of products and services in more than 125 countries. www.phchd.com

Apple, the Apple logo, and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. The Bluetooth® wordmark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks herein is under license. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.

For more media enquiries, please contact:

Amanda Clark, Amanda.Clark@Ascensia.com